fam199x Antibody

What is FAM199X and what are its key characteristics?

FAM199X (Family with Sequence Similarity 199, X-Linked) is a protein encoded by a gene located on the X chromosome. It is also known as CXorf39 or hypothetical protein LOC139231 in some databases . The protein consists of 388 amino acids and has been identified in various species including humans, Xenopus laevis, Xenopus tropicalis, and Danio rerio (zebrafish), suggesting evolutionary conservation . The human FAM199X protein sequence includes several structural domains and motifs, though the complete functional characterization remains an active area of research. The protein's amino acid sequence includes several distinct regions that may be important for its biological function, including a partial sequence: WSAMTNDEQVEYIEYLSRKVSTEMGLREQLDIIKIIDPSAQISPTDSEFIIELNCLTDEKLKQVRNYIKEHSPRQRPAREAWKRSNFSCASTSGVSGASASASSSSASMVSSASSSGSSVGNSASNSSA .

What antibody types are available for FAM199X research?

Several types of antibodies targeting FAM199X are currently available for research purposes, each with specific characteristics suited for different experimental applications:

These antibodies have been developed against specific epitopes of the FAM199X protein. For instance, the Novus Biologicals antibody was developed against a recombinant protein corresponding to a specific amino acid sequence of the human FAM199X protein . When selecting an antibody for your research, consider both the target species and the intended application, as validation data may be limited to specific experimental contexts.

How should FAM199X antibodies be stored and handled to maintain optimal activity?

For optimal preservation of antibody function, FAM199X antibodies should typically be stored at 4°C for short-term use (days to weeks) . For long-term storage, aliquoting and maintaining at -20°C is recommended to avoid repeated freeze-thaw cycles that can degrade antibody structure and function . Most FAM199X antibodies are supplied in a buffer containing PBS (pH 7.2) with 40% glycerol and 0.02% sodium azide as a preservative .

It's critical to avoid repeated freeze-thaw cycles, as these can lead to protein denaturation, aggregation, and loss of binding affinity. When working with FAM199X antibodies, allow them to reach room temperature before opening the vial to prevent condensation that could introduce contaminants. For diluted working solutions, prepare them fresh on the day of experiment whenever possible, and store any remaining solution according to the manufacturer's recommendations, typically at 4°C for short periods (1-2 weeks).

What applications are FAM199X antibodies validated for?

FAM199X antibodies have been validated for several common research applications, with varying recommended dilutions or concentrations:

When implementing these applications, it's advisable to begin with the manufacturer's recommended dilution range and optimize based on your specific experimental conditions. Proper controls, including negative controls (isotype control or pre-immune serum) and positive controls (samples known to express FAM199X), should be included to validate specificity and minimize background signals.

How can I validate the specificity of a FAM199X antibody for my research model?

Validating antibody specificity is crucial for generating reliable experimental data. For FAM199X antibodies, implement a multi-faceted validation approach:

• Genetic validation: Use FAM199X knockout or knockdown models (CRISPR-Cas9, siRNA, or shRNA) to confirm signal reduction or elimination when the target protein is absent.

• Cross-species reactivity testing: If working with non-human models, verify antibody cross-reactivity with your species of interest, as FAM199X antibodies have varying species reactivity profiles .

• Specific peptide blocking: Pre-incubate the antibody with the immunizing peptide before application to confirm signal elimination in positive samples.

• Multi-technique concordance: Validate results across multiple techniques (e.g., Western blot, immunofluorescence, and immunoprecipitation) to confirm consistent detection patterns.

• Protein array testing: Some FAM199X antibodies have undergone validation using protein arrays containing the target protein plus numerous non-specific proteins to verify selective binding . Review whether your antibody has undergone similar testing.

For optimal validation, include appropriate positive controls (tissues or cell lines with confirmed FAM199X expression) and negative controls (tissues or cell lines without FAM199X expression) in each experiment. Additionally, compare results from multiple antibody clones or from different vendors when feasible to strengthen confidence in your findings.

What are the optimal conditions for immunohistochemical detection of FAM199X in different tissue types?

Successful immunohistochemical detection of FAM199X requires careful optimization of several parameters:

• Fixation method: For most applications, 10% neutral buffered formalin fixation for 24-48 hours is recommended, though shorter fixation times may improve epitope accessibility.

• Antigen retrieval:

  • Heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) is generally effective

  • For challenging tissues, try alternative buffers such as EDTA (pH 8.0) or Tris-EDTA (pH 9.0)

  • Optimization of retrieval time (10-30 minutes) may be necessary for different tissue types

• Blocking conditions:

  • 5-10% normal serum (from the same species as the secondary antibody)

  • 1-3% BSA in PBS

  • Consider adding 0.1-0.3% Triton X-100 for improved permeabilization

• Primary antibody dilution: Start with the manufacturer's recommended range (1:10-1:500) and optimize for your specific tissue. Incubate overnight at 4°C for optimal signal-to-noise ratio.

• Detection system:

  • For formalin-fixed paraffin-embedded tissues, polymer-based detection systems often provide superior sensitivity

  • For frozen sections, consider fluorescent secondary antibodies for multicolor analysis

• Counterstaining: Use hematoxylin for brightfield or DAPI for fluorescence to provide cellular context for FAM199X localization.

When working with difficult tissues or limited samples, consider performing a dilution series of the primary antibody to determine the optimal concentration that maximizes specific signal while minimizing background. Tissue-specific modifications may be necessary, particularly for tissues with high endogenous biotin or peroxidase activity.

How can I monitor and ensure the stability of FAM199X antibodies for long-term research projects?

Maintaining antibody stability throughout a long-term research project is essential for consistent results. Implement these stability monitoring strategies:

• Aliquoting strategy: Upon receipt, divide the antibody into small single-use aliquots to minimize freeze-thaw cycles, which can significantly impact stability .

• Storage temperature monitoring: Maintain a temperature log for freezers and refrigerators where antibodies are stored, with alarm systems for temperature deviations.

• Periodic functional testing: At regular intervals (e.g., every 3-6 months), test antibody performance using:

  • ELISA to evaluate binding activity to recombinant FAM199X protein

  • Western blot with positive control lysates to confirm expected banding pattern

  • Immunostaining of known positive samples to verify localization patterns

• Reference standard comparison: Maintain a reference aliquot from the initial lot and compare new lots or aging antibodies against this standard.

• Physical assessment:

  • Check for visible precipitates or turbidity that may indicate protein aggregation

  • Monitor solution color changes that might suggest contamination

• Documentation system: Maintain detailed records of antibody performance over time, including:

  • Lot numbers and purchase dates

  • Number of freeze-thaw cycles

  • Observed signal intensity in standardized assays

  • Images from quality control experiments

What is the recommended protocol for quantifying FAM199X expression using immunofluorescence techniques?

For accurate quantification of FAM199X expression using immunofluorescence, a standardized protocol with careful consideration of experimental variables is essential:

• Sample preparation:

  • Fix cells with 4% paraformaldehyde for 15-20 minutes at room temperature

  • Permeabilize with 0.1-0.3% Triton X-100 in PBS for 10 minutes

  • Block with 5% normal serum and 1% BSA in PBS for 1 hour

• Antibody application:

  • Apply FAM199X primary antibody at optimized concentration (typically 1-4 μg/ml)

  • Incubate overnight at 4°C in a humidified chamber

  • Wash thoroughly with PBS (3 × 5 minutes)

  • Apply fluorophore-conjugated secondary antibody (1:500-1:1000) for 1 hour at room temperature

  • Counterstain nuclei with DAPI

• Image acquisition standardization:

  • Use identical exposure settings for all samples and controls

  • Capture multiple random fields per sample (minimum 5-10)

  • Include z-stack imaging if subcellular localization is important

  • Always image experimental and control samples in the same session

• Quantification methodology:

  • For mean fluorescence intensity: measure integrated density and subtract background

  • For co-localization analysis: calculate Pearson's or Mander's coefficients

  • For population analysis: determine percentage of positive cells using threshold-based segmentation

• Data analysis and normalization:

  • Normalize to cell number or nuclear count

  • Consider cell cycle stage if FAM199X expression varies with proliferation

  • Use appropriate statistical tests for comparing experimental groups

Include appropriate controls: isotype control antibody, secondary-only control, and positive control samples with known FAM199X expression levels. For multi-condition experiments, consider automated image analysis pipelines using software such as ImageJ/FIJI, CellProfiler, or QuPath to ensure consistent quantification across all samples.

How can I troubleshoot non-specific binding issues with FAM199X antibodies?

Non-specific binding is a common challenge when working with antibodies. For FAM199X antibodies specifically, consider these troubleshooting approaches:

• Optimize blocking conditions:

  • Increase blocking serum concentration to 5-10%

  • Try alternative blocking agents (BSA, casein, commercial blocking buffers)

  • Extend blocking time to 1-2 hours at room temperature

• Adjust antibody concentration:

  • Perform a titration series to identify the optimal concentration that maximizes specific signal while minimizing background

  • For Western blots, typically start with 1:1000 dilution

  • For immunohistochemistry, begin with recommended range (1:10-1:500) and adjust as needed

• Modify washing procedures:

  • Increase number of washes (5-6 times instead of 3)

  • Extend wash duration (10 minutes per wash)

  • Add 0.05-0.1% Tween-20 to wash buffers to reduce hydrophobic interactions

• Improve tissue preparation:

  • Ensure complete fixation but avoid overfixation

  • Optimize antigen retrieval conditions

  • Block endogenous enzyme activity (peroxidase, alkaline phosphatase) before antibody application

• Address specific sources of background:

  • For high endogenous biotin: use biotin blocking kits or avoid biotin-based detection systems

  • For autofluorescence: use Sudan Black B (0.1-0.3%) treatment or commercial autofluorescence quenchers

  • For sticky tissues (brain, fat): add 0.1-0.3% Triton X-100 to antibody diluent

• Antibody purification considerations:

  • Affinity-purified antibodies typically show lower background than whole serum

  • Consider pre-adsorption against tissues or lysates from species of interest

If non-specific binding persists despite these optimizations, consider testing alternative FAM199X antibody clones or sources, as different antibodies may perform better in specific applications or with particular sample types.

How should I design experiments to study FAM199X colocalization with other cellular proteins?

Designing robust colocalization experiments requires careful consideration of antibody compatibility, imaging parameters, and quantitative analysis:

When publishing colocalization studies, include both representative images and quantitative analysis of multiple cells (typically >30) across at least three independent experiments. Consider super-resolution microscopy techniques (STED, STORM, SIM) for studying closely associated proteins where the distance between them approaches the diffraction limit of conventional microscopy.

What are the recommended controls for validating FAM199X antibody specificity in Western blot applications?

Comprehensive validation of FAM199X antibody specificity in Western blot requires multiple controls:

• Positive and negative cell/tissue lysates:

  • Positive control: lysates from cells/tissues known to express FAM199X

  • Negative control: lysates from cells/tissues with minimal or no FAM199X expression

  • When available, use knockout or knockdown samples as definitive negative controls

• Peptide competition assay:

  • Pre-incubate the antibody with excess immunizing peptide

  • Run parallel blots with competed and non-competed antibody

  • Specific bands should be eliminated or significantly reduced in the competed sample

• Molecular weight verification:

  • Human FAM199X protein has a predicted molecular weight that should be verified

  • Look for additional bands that might represent isoforms, post-translational modifications, or degradation products

• Loading controls:

  • Include housekeeping protein detection (β-actin, GAPDH, tubulin) to verify equal loading

  • Consider Ponceau S staining of membranes before blocking to visualize total protein

• Antibody technical controls:

  • Secondary antibody only: omit primary antibody to detect non-specific secondary binding

  • Isotype control: use non-specific IgG from the same species at equivalent concentration

  • Cross-reactivity test: if studying multiple species, verify specificity for each species

• Recombinant protein standard:

  • Include a lane with purified recombinant FAM199X protein as a size reference

  • This can also serve as a positive control for antibody reactivity

Document all validation steps thoroughly, including images of complete blots rather than cropped bands, to demonstrate antibody specificity convincingly. Remember that antibody validation is not a one-time process but should be repeated periodically to ensure consistent performance throughout a research project.

How can I optimize FAM199X immunoprecipitation protocols for protein-protein interaction studies?

Successful immunoprecipitation (IP) of FAM199X for protein interaction studies requires optimization of several critical parameters:

• Lysis buffer selection:

  • Start with a gentle, non-denaturing buffer (e.g., 1% NP-40 or 0.5% Triton X-100, 150mM NaCl, 50mM Tris pH 7.5)

  • Include protease inhibitors (complete cocktail) and phosphatase inhibitors if studying phosphorylation-dependent interactions

  • Consider adding 1-2mM EDTA to chelate metal ions that might affect protein interactions

  • For nuclear proteins that may interact with FAM199X, include DNase/RNase treatment

• Pre-clearing strategy:

  • Pre-clear lysates with Protein A/G beads for 1 hour at 4°C

  • This reduces non-specific binding to beads in subsequent steps

  • Filter lysates if debris is problematic (0.45μm filter)

• Antibody binding optimization:

  • Test different antibody amounts (typically 1-5μg per mg of total protein)

  • Optimize incubation time (4 hours to overnight at 4°C with gentle rotation)

  • Consider cross-linking antibody to beads with dimethyl pimelimidate to prevent antibody co-elution

• Washing conditions:

  • Start with 4-5 washes in lysis buffer

  • Consider increasing salt concentration in later washes (up to 300mM NaCl) to reduce non-specific interactions

  • Balance stringency with preservation of specific interactions

• Elution methods:

  • Gentle: non-denaturing elution with competing peptide

  • Standard: denaturing elution with SDS sample buffer at 95°C

  • If mass spectrometry analysis is planned, consider acid elution or on-bead digestion

• Verification approaches:

  • Immunoblot for FAM199X to confirm successful IP

  • Immunoblot for suspected interaction partners

  • For discovery of novel interactions, consider mass spectrometry analysis

For detecting transient or weak interactions, consider using crosslinking agents (DSP, formaldehyde) before cell lysis. When analyzing results, compare with appropriate controls including IP with isotype-matched control antibody and IP from cells lacking FAM199X expression to identify truly specific interactions.

What approaches can be used to study FAM199X expression across different developmental stages or disease states?

Comprehensive analysis of FAM199X expression patterns across developmental stages or disease progression requires multi-modal approaches:

• Tissue microarray (TMA) analysis:

  • Allows simultaneous analysis of FAM199X expression across multiple tissue samples

  • Particularly useful for comparing normal versus pathological tissues

  • Use standardized IHC protocols with FAM199X antibody (1:10-1:20 dilution recommended)

  • Quantify using digital pathology software for consistent scoring

• Developmental stage comparison:

  • For model organisms (zebrafish, Xenopus), examine FAM199X expression at defined developmental time points

  • Consider whole-mount immunostaining for embryonic samples

  • Coordinate with in situ hybridization for mRNA expression patterns

• Single-cell analysis approaches:

  • Single-cell RNA-seq to identify cell populations expressing FAM199X

  • Multiplex immunofluorescence to correlate FAM199X with cell type-specific markers

  • Mass cytometry (CyTOF) if antibodies are compatible with metal conjugation

• Quantitative analysis methods:

  • RT-qPCR for mRNA expression across samples

  • Western blot with densitometry for protein-level quantification

  • ELISA development for high-throughput quantification in multiple samples

• In vivo imaging:

  • For animal models, consider reporter constructs (FAM199X promoter driving fluorescent protein)

  • Longitudinal imaging to track expression changes over time

  • Correlate with disease progression or developmental milestones

• Database mining and bioinformatics:

  • Analyze public gene expression datasets for FAM199X across tissues, developmental stages, or disease states

  • Perform correlation analyses with other genes to identify potential functional relationships

  • Use pathway enrichment analysis to place FAM199X in biological context

How should I approach epitope mapping for FAM199X antibodies to better understand their binding characteristics?

Epitope mapping provides crucial information about antibody specificity and can inform experimental design. For FAM199X antibodies, consider these approaches:

• Peptide array analysis:

  • Synthesize overlapping peptides (15-20 amino acids with 5-10 amino acid overlap) spanning the FAM199X sequence

  • Spot peptides onto membranes and probe with the antibody of interest

  • Identify reactive peptides to narrow down epitope regions

  • Focus particularly on the region: WSAMTNDEQVEYIEYLSRKVSTEMGLREQLDIIKIIDPSAQISPTDSEFIIELNCLTDEKLKQVRNYIKEHSPRQRPAREAWKRSNFSCASTSGVSGASASASSSSASMVSSASSSGSSVGNSASNSSA

• Truncation mutant analysis:

  • Generate a series of truncated FAM199X constructs

  • Express in a heterologous system lacking endogenous FAM199X

  • Perform Western blot analysis to identify the minimal region recognized by the antibody

• Alanine scanning mutagenesis:

  • For fine mapping, create point mutations replacing key residues with alanine

  • Focus on charged or polar residues within the suspected epitope region

  • Test antibody binding to identify critical residues for recognition

• Computational prediction:

  • Use epitope prediction algorithms to identify likely antigenic regions

  • Compare with experimental results to refine mapping

  • Consider structural information if available (predicted or experimental)

• Cross-species reactivity analysis:

  • Compare FAM199X sequences across species (human, Xenopus, zebrafish)

  • Test antibody reactivity against FAM199X from different species

  • Conserved epitopes may indicate functionally important regions

Understanding the specific epitope recognized by your FAM199X antibody allows you to:

• Predict potential cross-reactivity with related proteins

• Determine if post-translational modifications might affect antibody binding

• Assess whether the epitope is accessible in different experimental conditions

• Design better blocking peptides for specificity controls

This information is particularly valuable when working with multiple FAM199X antibodies, as antibodies targeting different epitopes can provide complementary information and serve as validation tools for each other.

What are the considerations for developing a quantitative ELISA assay for FAM199X protein detection?

Developing a reliable quantitative ELISA for FAM199X requires careful optimization of multiple parameters:

• Assay format selection:

  • Sandwich ELISA: Requires two antibodies recognizing different FAM199X epitopes

  • Direct ELISA: Simpler but potentially less specific; useful with purified samples

  • Competitive ELISA: Good for small proteins or when limited epitopes are available

• Antibody pair optimization (for sandwich ELISA):

  • Test different capture antibody concentrations (typically 1-10 μg/ml)

  • Optimize detection antibody dilution

  • Consider monoclonal capture with polyclonal detection for maximum sensitivity

  • Test orientation (which antibody for capture vs. detection) as this can affect sensitivity

• Standard curve development:

  • Use purified recombinant FAM199X protein for standard curve

  • Prepare standards in the same matrix as samples to minimize background effects

  • Standard range typically spanning 2-3 orders of magnitude

  • Include quality controls at low, medium, and high concentrations

• Sample preparation considerations:

  • Optimize lysis buffer compatible with ELISA (avoid detergents above critical micelle concentration)

  • Determine appropriate sample dilution factors

  • Consider sample pre-clearing steps if high background is observed

• Assay validation parameters:

  • Sensitivity: Determine limit of detection (LOD) and limit of quantification (LOQ)

  • Specificity: Test related proteins and sample matrix effects

  • Precision: Assess intra-assay and inter-assay coefficients of variation (CV <15% typically acceptable)

  • Linearity: Evaluate dilutional linearity of actual samples

  • Recovery: Spike known amounts of recombinant FAM199X into samples

• Protocol optimization:

  • Incubation times and temperatures

  • Blocking buffer composition (typically 1-5% BSA or milk proteins)

  • Wash buffer composition and washing technique

  • Substrate selection for optimal signal-to-noise ratio

For all optimization steps, perform experiments in at least triplicate and include appropriate controls. Once developed, validate the assay with biological samples where FAM199X levels are altered (e.g., overexpression systems, knockdown samples) to confirm the assay accurately reflects biological differences in FAM199X expression.

How can I ensure reproducibility in FAM199X antibody-based experiments across different research groups or laboratories?

Ensuring reproducibility of FAM199X antibody experiments across different laboratories requires standardization of protocols, reagents, and reporting:

• Detailed protocol documentation:

  • Create step-by-step protocols with explicit timing, temperatures, and reagent compositions

  • Include troubleshooting guides addressing common issues

  • Document all equipment settings (microscope parameters, blot imaging conditions)

  • Consider publishing protocols in journals like Bio-protocol or protocols.io

• Antibody standardization:

  • Use antibodies with unique identifiers (catalog numbers, RRID numbers)

  • Document lot numbers in all experiments

  • Consider antibody validation programs (e.g., EuroMAbNet, Antibodypedia) for independent validation

  • Share aliquots of validated antibody lots between collaborating laboratories

• Sample preparation harmonization:

  • Standardize fixation protocols (fixative type, concentration, duration, temperature)

  • Use identical lysis buffers and protein quantification methods

  • Consider centralized sample processing for multi-site studies

• Controls and validation:

  • Distribute reference samples to all participating laboratories

  • Include identical positive and negative controls in all experiments

  • Consider spike-in standards for quantitative applications

  • Implement blinded analysis to reduce bias

• Data sharing and analysis:

  • Use common data formats and analysis pipelines

  • Share raw data along with processed results

  • Consider centralized analysis of raw data from multiple sites

  • Document software versions and parameters used for analysis

• Implementation of quality control metrics:

  • Define acceptance criteria before experiments begin

  • Implement regular proficiency testing between laboratories

  • Use statistical methods appropriate for multi-site data

  • Consider preliminary inter-laboratory comparison studies before major projects

For collaborative projects, consider establishing a reference laboratory that can validate critical reagents and train participants in standardized techniques. Regular video conferences to discuss technical challenges can help identify and resolve issues early. Finally, ensure transparent reporting of all methodological details in publications, following initiatives like the Antibody Validation Initiative guidelines or the Minimum Information About a Protein Affinity Reagent (MIAPAR) standards.

What stability testing protocols should be implemented for long-term storage of FAM199X antibodies?

Implementing a comprehensive stability testing program for FAM199X antibodies ensures reliable performance throughout long-term storage:

• Initial characterization tests:

  • Protein concentration verification (A280 measurement, BCA assay)

  • SDS-PAGE analysis to assess purity and integrity

  • Functional activity testing (ELISA, Western blot, immunostaining)

  • Aggregation assessment (size exclusion chromatography, dynamic light scattering)

• Storage condition evaluation:

  • Test multiple storage formats:

    • Concentrated stock at -80°C, -20°C, and 4°C

    • Working dilutions at -20°C and 4°C

    • Lyophilized formats if applicable

  • Evaluate different buffer compositions:

    • With/without glycerol (typically 40%)

    • With/without carrier proteins (BSA)

    • With/without preservatives (sodium azide 0.02%)

• Accelerated stability testing:

  • Incubate antibody aliquots at elevated temperatures (25°C, 37°C)

  • Test functionality at regular intervals (days 1, 3, 7, 14, 30)

  • Use Arrhenius equation to extrapolate long-term stability at lower temperatures

• Real-time stability monitoring:

  • Prepare multiple identical aliquots at time zero

  • Test aliquots at defined intervals (1, 3, 6, 12, 24 months)

  • Monitor the following parameters at each time point:

    • Binding activity (ELISA against target antigen)

    • Specificity (Western blot banding pattern)

    • Physical appearance (turbidity, precipitation)

    • pH stability

    • Functional application performance

• Freeze-thaw stability:

  • Subject aliquots to defined numbers of freeze-thaw cycles (1, 3, 5, 10)

  • Evaluate activity and physical characteristics after each cycle

  • Determine maximum acceptable number of cycles

• Photostability testing:

  • Expose aliquots to light (ambient and UV) for varying durations

  • Assess impact on antibody performance

  • Determine appropriate light protection measures

Documentation is crucial for stability programs. Maintain detailed records including lot numbers, testing dates, methodologies, and results. Based on collected data, establish evidence-based storage recommendations, shelf-life claims, and handling guidelines for FAM199X antibodies. This approach mirrors pharmaceutical stability testing protocols outlined in search result , adapting them specifically for research antibodies.

What are emerging applications of FAM199X antibodies in single-cell analysis techniques?

FAM199X antibodies are increasingly being incorporated into cutting-edge single-cell analysis techniques, opening new avenues for understanding protein expression heterogeneity:

• Mass cytometry (CyTOF) integration:

  • Metal-conjugated FAM199X antibodies allow simultaneous detection with dozens of other markers

  • Enables correlation of FAM199X expression with cell lineage markers and signaling states

  • Consider metal selection to avoid spillover with commonly used markers

  • Validate metal-conjugated antibodies against conventional detection methods

• Imaging mass cytometry applications:

  • Combines spatial resolution with multi-parameter detection

  • Allows visualization of FAM199X expression in tissue architectural context

  • Enables quantification of expression levels in specific cell types within tissues

  • Consider optimizing antibody concentration specifically for this application

• Single-cell Western blotting:

  • Microfluidic platforms allow protein analysis at single-cell resolution

  • Requires highly specific FAM199X antibodies with low background

  • Enables correlation of protein size variants with cellular phenotypes

  • Consider sensitivity limitations compared to bulk analysis

• Proximity ligation assays (PLA):

  • Detect protein-protein interactions involving FAM199X at single-molecule resolution

  • Requires pair of antibodies (anti-FAM199X plus antibody against potential interacting partner)

  • Can be performed in fixed cells/tissues to preserve spatial information

  • Suitable for rare interactions that may be diluted in bulk analyses

• CITE-seq and REAP-seq applications:

  • Antibody-based detection combined with single-cell RNA sequencing

  • Oligonucleotide-conjugated FAM199X antibodies required

  • Correlates protein expression with transcriptomic profiles

  • Consider epitope accessibility in fixed/permeabilized cells

For all these applications, validation of FAM199X antibodies in the specific methodological context is essential, as performance may differ significantly from conventional applications. Start with cell lines with known FAM199X expression levels before advancing to complex primary samples. Additionally, computational analysis pipelines may need to be customized for optimal interpretation of FAM199X data in multi-parameter datasets.

How can I design knockdown/overexpression experiments to validate FAM199X antibody specificity and function?

Designing effective genetic manipulation experiments is critical for validating FAM199X antibody specificity and investigating protein function:

• Knockdown experiment design:

  • siRNA approach:

    • Design 3-4 siRNA sequences targeting different regions of FAM199X mRNA

    • Include non-targeting control siRNA

    • Optimize transfection conditions for your cell type

    • Assess knockdown efficiency 48-72 hours post-transfection

  • shRNA approach (for stable knockdown):

    • Design shRNA sequences based on validated siRNA sequences

    • Use inducible promoter systems for temporal control

    • Generate stable cell lines through antibiotic selection

    • Validate clones for knockdown efficiency

  • CRISPR-Cas9 approach (for knockout):

    • Design 3-4 guide RNAs targeting early exons of FAM199X

    • Include non-targeting control guides

    • Screen clones by genomic PCR and sequencing

    • Confirm protein loss by Western blot with FAM199X antibody

• Overexpression experiment design:

  • Construct considerations:

    • Full-length human FAM199X cDNA (388 amino acids)

    • Consider epitope tags (FLAG, HA, GFP) for detection

    • Use codon-optimized sequences for improved expression

    • Include vector-only controls

  • Expression system selection:

    • Transient transfection for short-term studies

    • Stable cell lines for long-term functional studies

    • Inducible systems to control expression level and timing

    • Consider viral vectors for difficult-to-transfect cells

• Validation approaches:

  • Transcript level verification:

    • RT-qPCR to confirm mRNA changes

    • Consider primers spanning exon-exon junctions

  • Protein level verification:

    • Western blot with FAM199X antibody

    • If tagged, detect with both tag antibody and FAM199X antibody

    • Immunofluorescence to assess expression level and localization

• Functional readouts:

  • Proliferation assays

  • Cell cycle analysis

  • Subcellular localization studies

  • Protein interaction studies (co-IP, proximity ligation)

  • Phenotypic assays relevant to suspected function

These manipulated systems serve as critical controls for antibody validation. A specific FAM199X antibody should show reduced or absent signal in knockdown/knockout samples and increased signal in overexpression samples. Additionally, these systems enable investigation of FAM199X function by correlating protein levels with phenotypic changes. Include rescue experiments, where the knockdown phenotype is reversed by expression of an siRNA-resistant FAM199X variant, to confirm specificity of observed effects.

What considerations should be made when developing multiplex immunofluorescence panels including FAM199X?

Developing multiplex immunofluorescence panels that include FAM199X requires careful planning to optimize signal detection while minimizing cross-reactivity and spectral overlap:

• Antibody selection considerations:

  • Host species compatibility:

    • Choose primary antibodies raised in different host species

    • If multiple rabbit antibodies must be used, consider sequential staining with thorough blocking between rounds

    • Evaluate directly conjugated primary antibodies to reduce species limitations

  • Isotype compatibility:

    • Use subclass-specific secondary antibodies when primaries come from same species

    • Validate specificity of subclass detection

  • FAM199X antibody performance:

    • Test optimal dilution in single-color staining first (start with 1-4 μg/ml)

    • Evaluate fixation conditions that preserve FAM199X epitope while compatible with other targets

    • Verify subcellular localization pattern of FAM199X

• Fluorophore selection strategy:

  • Spectral considerations:

    • Choose fluorophores with minimal spectral overlap

    • Place brightest fluorophores with weakest antigens

    • Consider brightness hierarchy (typical order: AF647>AF488>AF555>AF594)

    • Evaluate autofluorescence spectrum of your tissue/cells and avoid those wavelengths

  • Signal balancing:

    • Adjust antibody concentrations to achieve balanced signal intensity

    • Consider dynamic range of each fluorophore

    • Test different fluorophore combinations for optimal signal separation

• Protocol optimization:

  • Antigen retrieval:

    • Test different methods (heat, enzymatic, pH conditions)

    • Find conditions compatible with all antigens in the panel

    • Consider tyramide signal amplification for low-abundance targets

  • Blocking strategy:

    • Use serum from species of all secondary antibodies

    • Consider specialized blocking for endogenous biotin, Fc receptors

    • Test different blocking durations and concentrations

• Panel validation approaches:

  • Single-color controls:

    • Stain separate samples with each primary antibody alone

    • Verify expected staining pattern and absence of cross-reactivity

  • Fluorescence-minus-one (FMO) controls:

    • Prepare samples with all antibodies except one

    • Use to set threshold gates and assess spillover

  • Sequential vs. simultaneous staining comparison:

    • Test if antibody performance differs between approaches

    • Consider sequential staining for problematic antibody combinations

For analysis, implement appropriate spectral unmixing if using closely related fluorophores. Consider automated multispectral imaging platforms (Vectra, Mantra) for tissues with high autofluorescence. Document panel development meticulously to ensure reproducibility, and be prepared to revise the panel iteratively based on validation results.

What are the most common causes of false positive or false negative results when using FAM199X antibodies and how can they be mitigated?

Understanding and addressing common sources of false results is essential for generating reliable data with FAM199X antibodies:

False Positive Results:

• Cross-reactivity issues:

  • Problem: Antibody binding to proteins with similar epitopes

  • Solution: Verify specificity with knockout/knockdown controls; perform peptide competition assays; use multiple antibodies targeting different epitopes

• Non-specific binding:

  • Problem: Hydrophobic interactions or Fc receptor binding

  • Solution: Optimize blocking (5-10% serum, 1-3% BSA); add 0.1-0.3% Triton X-100 to reduce hydrophobic interactions; include Fc receptor blocking for immune cells

• Endogenous enzyme activity:

  • Problem: Endogenous peroxidase or phosphatase activity in IHC/ICC

  • Solution: Include enzyme quenching steps (3% H₂O₂ for peroxidase, levamisole for alkaline phosphatase)

• Detection system artifacts:

  • Problem: Non-specific binding of secondary antibodies or detection reagents

  • Solution: Include secondary-only controls; use cross-adsorbed secondary antibodies; titrate detection reagents

False Negative Results:

• Epitope masking:

  • Problem: Fixation-induced epitope changes or protein-protein interactions hiding the epitope

  • Solution: Test multiple fixation methods; optimize antigen retrieval conditions; try reducing agents to break disulfide bonds

• Insufficient sensitivity:

  • Problem: Low antibody affinity or low target abundance

  • Solution: Increase antibody concentration; extend incubation time (overnight at 4°C); implement signal amplification (TSA, polymer detection systems)

• Degraded antibody:

  • Problem: Loss of antibody activity during storage

  • Solution: Store according to manufacturer recommendations (4°C short-term, -20°C with glycerol long-term) ; avoid freeze-thaw cycles; include positive controls in each experiment

• Sample preparation issues:

  • Problem: Overfixation or protein degradation

  • Solution: Standardize fixation timing; add protease inhibitors to lysates; process samples quickly and consistently

General Mitigation Strategies:

• Comprehensive controls:

  • Positive and negative tissue/cell controls

  • Isotype controls at the same concentration as primary antibody

  • Technical controls (secondary-only, substrate-only)

• Validation across methods:

  • Confirm findings with orthogonal techniques (e.g., IF results with Western blot)

  • Use genetic manipulation to validate antibody specificity

• Quantitative approach:

  • Implement scoring systems with defined thresholds

  • Use digital image analysis for objective quantification

  • Conduct blinded assessment to reduce bias

By implementing these systematic approaches to identify and address potential sources of false results, researchers can significantly improve the reliability of data generated with FAM199X antibodies across various applications.

How do different sample preparation methods affect FAM199X epitope availability and antibody performance?

Sample preparation methods can dramatically influence FAM199X detection by affecting epitope availability and protein localization:

• Fixation effects:

  Fixation Method	Impact on FAM199X Detection	Best Applications	Limitations
  4% Paraformaldehyde (PFA)	Preserves protein structure with moderate epitope masking	Standard for ICC/IF, IHC	May require antigen retrieval for some epitopes
  Methanol	Precipitates proteins, disrupts certain epitopes while exposing others	Rapid fixation, good for certain cytoskeletal proteins	Can distort membrane structures, may affect FAM199X localization
  Acetone	Similar to methanol but generally milder	Quick fixation for frozen sections	Poor morphological preservation
  Glutaraldehyde	Strong cross-linking, excellent morphology	Electron microscopy	Significant epitope masking, high autofluorescence
  Heat-mediated fixation	Rapid protein denaturation	FFPE tissue preparation	Requires optimized antigen retrieval

• Antigen retrieval optimization:

  • Heat-induced epitope retrieval (HIER):

    • Citrate buffer (pH 6.0): Often effective for moderately masked epitopes

    • EDTA buffer (pH 8.0-9.0): More aggressive retrieval for heavily fixed samples

    • Tris-EDTA: Alternative for certain epitopes resistant to citrate retrieval

  • Enzymatic retrieval:

    • Proteinase K: Can expose heavily masked epitopes

    • Trypsin: Milder option for moderately fixed tissues

    • Risk of excessive digestion leading to tissue damage

• Permeabilization considerations:

  • Triton X-100 (0.1-0.5%): Effective for nuclear and cytoplasmic epitopes

  • Saponin (0.1-0.5%): Milder, reversible permeabilization for membrane proteins

  • Digitonin (0.001-0.01%): Selective for plasma membrane, preserves nuclear envelope

  • No permeabilization: Necessary for detecting cell surface epitopes

• Tissue processing effects:

  • Fresh frozen: Minimal epitope masking but poorer morphology

  • FFPE: Excellent morphology but significant epitope masking requiring retrieval

  • Vibratome sections: No freezing or embedding artifacts, good for thick sections

  • Tissue clearing: Enables whole-mount staining but may affect antibody penetration

• Cell preparation methods:

  • Cytospin: Good for suspension cells, maintains morphology

  • Smears: Rapid but can distort cellular architecture

  • Grown on coverslips: Optimal for adherent cells, maintains in situ relationships

  • Flow cytometry preparation: Often requires gentler fixation and optimization of permeabilization

When implementing a new detection protocol for FAM199X, systematically test multiple preparation methods. Document outcomes comprehensively, including signal intensity, background levels, and subcellular localization patterns. Consider that optimal conditions may vary based on tissue type, cell line, and the specific FAM199X epitope targeted by your antibody.

How should I address contradictory results between different FAM199X antibodies or detection methods?

Contradictory results between different FAM199X antibodies or detection methods require systematic investigation to resolve discrepancies:

• Characterize antibody differences:

  • Compare epitope regions:

    • Antibodies targeting different domains may detect different isoforms

    • N-terminal vs. C-terminal antibodies may give different results if processing occurs

  • Review validation data for each antibody:

    • Specificity testing (Western blot pattern, peptide competition)

    • Recommended applications (some antibodies work in WB but not IHC)

  • Verify clonality and host species:

    • Monoclonals detect single epitopes while polyclonals detect multiple epitopes

    • Different host species may have varying cross-reactivity profiles

• Methodology-based investigation:

  • Cross-method validation:

    • If antibody A works in Western blot but not IHC, confirm protein presence with antibody B in both methods

    • Use genetic manipulation (overexpression, knockdown) to verify specificity in each method

  • Method-specific optimizations:

    • For Western blot discrepancies: Test reducing vs. non-reducing conditions

    • For IHC/IF discrepancies: Compare different fixation and antigen retrieval protocols

    • For ELISA discrepancies: Test different coating buffers and blocking agents

• Biological explanation assessment:

  • Consider post-translational modifications:

    • Phosphorylation, glycosylation may mask epitopes differentially

    • Some antibodies may be modification-specific

  • Evaluate protein-protein interactions:

    • Binding partners may obscure certain epitopes in native conditions

    • Denatured vs. native protein conformations expose different epitopes

  • Assess subcellular localization effects:

    • Compartmentalization may affect accessibility

    • Different extraction methods may recover protein from different compartments

• Resolution strategies:

  • Orthogonal validation approaches:

    • Mass spectrometry to confirm protein identity

    • RNA-level analysis (RT-PCR, RNA-seq) to confirm expression

    • Proximity ligation assay to verify co-localization of multiple epitopes

  • Combinatorial approach:

    • Use multiple antibodies in the same experiment when possible

    • Report results from all antibodies with clear documentation of differences

  • Advanced techniques:

    • Super-resolution microscopy to resolve spatial discrepancies

    • CRISPR epitope tagging to create definitive detection method

• Reporting recommendations:

  • Document all experimental conditions thoroughly

  • Clearly state which antibody was used for each result

  • Acknowledge discrepancies transparently in publications

  • Provide hypotheses for observed differences

When facing contradictory results, avoid discarding data that doesn't match expectations. Instead, view discrepancies as opportunities to gain deeper insights into FAM199X biology, including potential isoforms, modifications, or context-dependent conformational changes that may have functional significance.